Update on toll‐like receptor‐directed therapies for human disease

AUTOR(ES)

Tse, Kevin

FONTE

BMJ Group

RESUMO

Innate responses to microbes are mediated in large part by toll‐like receptors (TLRs), which recognise a diverse range of molecules produced by viruses, bacteria and fungi. Great effort has been directed towards translating this knowledge into the development of new therapies for a wide spectrum of diseases, including infectious, malignant, autoimmune and allergic diseases. This review will provide a brief update on completed, ongoing and planned clinical trials of TLR ligand‐based therapies for the treatment of diseases in humans.

Documentos Relacionados

• Human lung cancer cells express functionally active Toll-like receptor 9
• Toll-like receptor 4 polymorphisms are associated with resistance to Legionnaires' disease
• Polymorphisms of toll-like receptor 2 and 4 genes in Chagas disease
• Impact of toll-like receptor 6 Pro249Ser and toll-like receptor 4 Asp299Gly polymorphisms on left ventricular structure in hypertensive patients
• Intact Gram-Negative Helicobacter pylori, Helicobacter felis, and Helicobacter hepaticus Bacteria Activate Innate Immunity via Toll-Like Receptor 2 but Not Toll-Like Receptor 4